佩奥尼佛洛林通过基于网络药理学分析的PI3K-AKT调节来改善性结肠炎
Qifang Li1, Shuyue Zheng2, Kai Niu2
1Department of Traditional Chinese Medicine, Affiliated Hospital of Jining Medical University, Jining, Shandong 272069, P.R. China.
Experimental and therapeutic medicine
|February 28, 2024
概括
佩奥尼佛林 (PF) 通过向关键炎症路径,有效治疗性结肠炎 (UC). 这项研究揭示了PF PF.
科学领域:
- 药理学和中国传统医学
- 计算生物学和网络医学
- 胃肠道学和免疫学
背景情况:
- 性结肠炎 (UC) 是一种慢性肠道炎症疾病.
- 来自Paeonia lactiflora的Paeoniflorin (PF) 是一种用于治疗UC的中国传统医药.
- 在UC治疗中PF的精确机制需要阐明.
研究的目的:
- 通过网络药理方法,研究Paeoniflorin (PF) 在性结肠炎 (UC) 中的治疗作用和分子机制.
- 确定参与PF反UC活动的关键目标和信号通路.
- 通过分子对接和动物实验验证这些发现.
主要方法:
- 网络药理学方法结合了目标预测,网络构建和途径分析 (GO,KEGG).
- 蛋白质与蛋白质相互作用网络分析以确定核心目标.
- 分子对接模拟以评估结合亲和力.
- 在体内实验中使用硫酸诱导UC的小鼠模型进行了体内实验.
主要成果:
- 确定了288个PF目标和599个UC目标,其中60个重叠的治疗目标,包括20个核心目标.
- 治疗PF调节的途径,如EGFR氨酸激酶抑制剂耐药性,IL-17信号传递和PI3K/AKT信号传递.
- 分子对接证实了PF和AKT1/EGFR之间的良好结合能量.
- 动物研究表明,PF改善了结肠损伤,减少了促炎性细胞因子 (IL-1β,IL-6,TNF-α) 和增加了抗炎性细胞因子 (IL-10,TGF-β).
- 在体内,PF降低了AKT1,EGFR,mTOR和PI3K的mRNA和蛋白质表达.
结论:
- 佩奥尼佛林 (PF) 显示出对性结肠炎 (UC) 的显著治疗潜力.
- PF主要通过调节PI3K/AKT信号通路来发挥其保护作用.
- 网络药理学与实验验证相结合,为了解传统医学机制提供了一个强大的框架.
更多相关视频
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
435
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
435
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
429
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
429
Phosphoinositides and PIPs
8.5K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.5K


